Intraretinal Fluid: Causes, Symptoms, and Treatment

Intraretinal fluid is an abnormal buildup of liquid within the layers of the retina, the thin tissue at the back of the eye responsible for converting light into the signals your brain reads as vision. It accumulates in specific retinal layers, particularly the outer plexiform layer and the inner nuclear layer, and is one of the key markers clinicians track in conditions like diabetic eye disease, age-related macular degeneration (AMD), and retinal vein occlusion. When this fluid collects in or near the macula, the central region that handles sharp reading and driving vision, even a small amount can blur or distort what you see.

How Fluid Ends Up Inside the Retina

The retina is protected by two barriers that tightly control what enters and exits the tissue. The inner blood-retinal barrier lines the small blood vessels inside the retina itself, and the outer blood-retinal barrier sits at the level of the retinal pigment epithelium (RPE), the cell layer just beneath the photoreceptors. Under normal conditions these barriers allow nutrients in and waste out while keeping excess fluid from seeping into retinal tissue. Intraretinal fluid appears when one or both of those barriers break down, tipping the balance so that more fluid enters the tissue than can be cleared away.¹

The driving force behind most barrier failures is a signaling molecule called vascular endothelial growth factor, or VEGF. When retinal tissue is starved of oxygen or inflamed, cells ramp up VEGF production, and VEGF makes blood vessel walls leaky. In diabetes, for example, chronic high blood sugar reduces oxygen delivery to the retina, which triggers VEGF upregulation and increased vascular permeability.² The same basic process plays out in AMD and vein occlusions, though the upstream trigger differs each time. In every case, the result is the same: fluid leaks through vessel walls into retinal layers where it does not belong.

The Most Common Conditions Behind Intraretinal Fluid

Diabetic macular edema (DME) is probably the most widely recognized cause. Poorly controlled blood sugar damages the tiny capillaries in the retina over years, and once those vessels start leaking, cyst-like pockets of fluid form within the retinal layers. DME can develop at any stage of diabetic retinopathy, though it becomes more likely as retinopathy worsens.

Neovascular (“wet”) AMD is the second major culprit. Here, abnormal new blood vessels grow beneath the retina and leak fluid, blood, or both. Post hoc analyses of major treatment trials have shown that the presence of intraretinal fluid in these patients is associated with worse visual outcomes than subretinal fluid alone, leading some researchers to recommend more aggressive treatment when intraretinal fluid is detected.³

Retinal vein occlusion (RVO), in which a clot or compression blocks the outflow of blood from the retina, is another frequent cause. When blood cannot drain normally, pressure builds inside the retinal vasculature and fluid leaks out. The edema can develop rapidly and, without treatment, persists for months.

Eye surgery can also trigger intraretinal fluid. The most common post-surgical scenario is Irvine-Gass syndrome, in which cataract surgery sets off an inflammatory cascade. Prostaglandins and VEGF released during that inflammation break down the blood-retinal barrier, producing cystoid macular edema weeks after an otherwise uneventful operation.⁴ Less commonly, vitreomacular traction, where the vitreous gel tugs on the macula as it separates, can create cyst-like spaces and intraretinal fluid.

What Intraretinal Fluid Feels Like

You cannot feel fluid inside the retina the way you feel a swollen ankle. There is no pain. What you notice instead is a change in vision, and the pattern depends on where the fluid sits. When it collects at or near the fovea, the center-most point of the macula, you may experience blurred central vision, difficulty reading fine print, or a sense that colors look washed out. Straight lines may appear wavy or bent, a distortion known as metamorphopsia. If the fluid is largely outside the fovea, you might not notice any symptoms at all in everyday life, even though imaging clearly shows swelling.

This is part of what makes intraretinal fluid tricky: moderate fluid in the periphery of the macula can be “silent” and only picked up on a routine scan, while even a tiny pocket right at the fovea can make reading a struggle. The symptoms are not specific to one disease. Blurred vision and distortion show up in DME, wet AMD, and vein occlusions alike, so the symptom alone does not tell your doctor what is causing the fluid.

How Doctors Detect and Measure It

Optical coherence tomography (OCT) is the workhorse of diagnosis. It takes cross-sectional images of the retina in seconds, revealing fluid pockets, cysts, and swelling that are invisible during a standard exam with a handheld lens. On an OCT scan, intraretinal fluid appears as dark (hyporeflective) spaces within the normally well-organized retinal layers. Clinicians can measure the thickness of the macula at precise points and track changes over weeks or months to judge whether treatment is working.

OCT is sensitive enough not only to detect fluid but also to give clues about its cause. Hard exudates (bright deposits of leaked lipids), the specific layers where cysts sit, and additional features like subretinal fluid or pigment epithelial detachments all point toward different diagnoses. Machine-learning algorithms trained on these OCT features have achieved sensitivity above 94% and specificity above 94% for distinguishing diabetic macular edema from post-surgical cystoid edema, for instance.⁵ In practice, though, doctors still combine OCT with a clinical exam, patient history, and sometimes a fluorescein angiogram (a dye test that shows leaking vessels) to pin down the cause.

Treatment With Anti-VEGF Injections

The most common frontline treatment for intraretinal fluid is an anti-VEGF injection delivered directly into the eye. Medications such as ranibizumab, aflibercept, and bevacizumab block the VEGF molecule that is driving vessel leakage, allowing the retinal barriers to tighten up and fluid to clear. These injections have transformed outcomes in wet AMD, DME, and RVO over the past two decades. They are given as a series, often monthly at first and then at extended intervals depending on how the eye responds.

Not every eye responds equally, though. In a post hoc analysis of the VIEW trials in wet AMD, roughly one in five to one in three eyes still had persistent fluid at week 52 depending on the treatment regimen. Eyes treated with the higher-dose aflibercept every four weeks showed greater average vision gains and fewer eyes losing significant vision compared with other dosing schedules, though many eyes achieved meaningful improvement regardless of the specific regimen.⁶ The takeaway for patients: if fluid persists despite several rounds of injections, switching to a different anti-VEGF drug or adjusting the dosing schedule is a reasonable next step, not a sign that treatment has “failed.”

Corticosteroid Implants and Other Options

When anti-VEGF injections alone do not clear the fluid, corticosteroid therapy is a well-established alternative, especially in DME and RVO. A dexamethasone intravitreal implant, a tiny biodegradable rod injected into the eye, releases steroid medication slowly over several months. In patients with retinal vein occlusion, a dexamethasone implant reduced average central macular thickness from over 600 micrometers down to around 230 micrometers within two months, with a meaningful jump in visual acuity.⁷ For diabetic macular edema that resists anti-VEGF therapy, a dexamethasone implant given alone or combined with anti-VEGF injections has been recommended as a viable option.⁸

Steroids carry their own trade-offs. They can raise the pressure inside the eye and accelerate cataract formation, so they are used more selectively than anti-VEGF drugs. Patients who are pseudophakic (already had cataract surgery and have an artificial lens) tolerate the cataract risk better, which is one reason steroid implants tend to be favored in that population.

Retinal laser photocoagulation, once the primary treatment for diabetic macular edema, is now used more as an adjunct. Laser works by destroying small patches of photoreceptors, which paradoxically reduces the retina’s overall oxygen demand. The improved oxygen balance causes retinal arteries to constrict, lowers capillary pressure, and decreases fluid leakage.⁹ Focal laser is still sometimes applied alongside anti-VEGF injections to reduce the overall treatment burden, though injections alone tend to produce better visual outcomes.

In selected cases, vitrectomy (surgical removal of the vitreous gel) may help. By removing the gel, the surgeon eliminates any traction it exerts on the macula and improves the circulation of oxygen and nutrients within the eye cavity, which can help resolve stubborn edema.⁹ Vitrectomy is most commonly considered when vitreomacular traction is contributing to the fluid buildup or when other treatments have not worked.

Why Persistent Fluid Matters for Long-Term Vision

The longer intraretinal fluid sits in the retina, the more damage it can do. In wet AMD, patients who spent the most time with intraretinal fluid over a year-long treatment period gained less improvement in vision-related quality of life compared with patients whose fluid cleared more quickly. Those in the highest quartile of fluid duration scored about two points lower on a standardized vision questionnaire than those in the lowest quartile.¹⁰ Two points on a 100-point scale might sound minor, but the pattern was consistent across multiple subscales measuring activities like reading, driving, and recognizing faces.

At a structural level, chronic intraretinal fluid appears to accelerate damage to the photoreceptor layer. A real-world analysis of neovascular AMD patients found that eyes with the highest volumes of intraretinal fluid had significantly more thinning and loss of the ellipsoid zone, the part of the photoreceptor layer that correlates most closely with visual function.¹¹ Once photoreceptors are lost, they do not regenerate in adults, so the damage can become permanent even if the fluid is eventually cleared. This is the main reason retinal specialists push for prompt, consistent treatment rather than adopting a wait-and-see approach when intraretinal fluid is present.

Intraretinal Fluid Versus Subretinal Fluid

On OCT scans, fluid can show up in more than one compartment. Intraretinal fluid sits within the retinal layers themselves, often forming small cyst-like cavities. Subretinal fluid pools in the narrow space between the photoreceptors and the RPE beneath them. A third type, sub-RPE fluid, forms beneath the RPE in what is called a pigment epithelium detachment. Each type carries somewhat different implications.

Across the large clinical trials in wet AMD, intraretinal fluid has consistently been the worst prognostic sign of the three. As noted in a review of trial data, intraretinal fluid whether at the fovea or outside it predicted poorer visual outcomes, while subretinal fluid in some studies was tolerated or even considered a normal variant in eyes with inactive drusen.³ This distinction has practical consequences: some treatment protocols in AMD now use the presence of intraretinal fluid specifically, rather than any fluid, as the trigger for retreatment. If your doctor mentions tolerating a small amount of subretinal fluid while monitoring more aggressively for intraretinal fluid, that is the rationale.

Systemic Risk Factors That Make Intraretinal Fluid Worse

Because the most common causes of intraretinal fluid are vascular diseases, what is happening in the rest of your body strongly influences what is happening in your retina. In diabetes, blood sugar control matters enormously. Higher hemoglobin A1c levels have been linked to a specific pattern of diffuse retinal thickening on OCT, one of the more difficult forms of diabetic macular edema to treat.¹²

Kidney function is another strong predictor. The small blood vessels in the retina and the small blood vessels in the kidneys are remarkably similar in structure, and damage to one often tracks with damage to the other. In a cross-sectional study of diabetic patients, the prevalence of macular edema roughly tripled among those with microalbuminuria (a sign of early kidney damage) compared with those whose kidneys were unaffected.¹³ Elevated blood pressure, high cholesterol, and sleep apnea have all been flagged as additional risk factors in various studies, though they tend to be less consistently associated than blood sugar and kidney function.

The practical upshot is that treating intraretinal fluid is not purely an eye problem. Tightening blood sugar control, managing blood pressure, and getting kidney function evaluated are all part of the picture, especially for people with diabetes. A retinal specialist can inject medication into the eye every month, but if the underlying systemic drivers remain uncontrolled, the fluid tends to return.

Post-Surgical Intraretinal Fluid

Cystoid macular edema after cataract surgery (Irvine-Gass syndrome) deserves its own mention because it catches many patients off guard. The surgery itself typically goes smoothly, and initial recovery looks normal. Then, usually four to twelve weeks later, central vision starts to blur as inflammatory mediators trigger fluid accumulation in the macula. The incidence on OCT is higher than the incidence of symptomatic cases, meaning some patients develop subclinical fluid that resolves on its own.

Topical anti-inflammatory eye drops, both nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are the first line of treatment. Most cases resolve within a few months. Stubborn cases may require a periocular or intravitreal steroid injection, and refractory cases have been treated with anti-VEGF injections.⁴ Patients who had complicated cataract surgery, such as those who experienced a posterior capsule rupture, are at higher risk, as are patients with diabetes or a history of uveitis (eye inflammation). If your vision starts to decline a month or two after cataract surgery, bringing it up with your surgeon promptly gives you the best chance of a quick resolution.

Emerging Role of AI in Fluid Monitoring

Retinal specialists typically evaluate OCT scans by eye, mentally grading the amount and location of fluid. That process is reliable but subjective, and as treatment intervals are extended to reduce the burden of frequent injections, the stakes of missing early fluid recurrence go up. Automated segmentation tools that use artificial intelligence to measure fluid volumes precisely are increasingly being studied as a way to standardize monitoring.

Early results suggest that AI-based segmentation can detect subtle changes in intraretinal fluid volume that a human grader might overlook, and can do so consistently across thousands of scans.¹⁴ In the real-world analysis linking fluid volumes to photoreceptor damage, automated quantification was the tool that made it feasible to correlate specific fluid volumes with specific structural losses across large patient cohorts.¹¹ These tools are not yet a standard part of every clinic visit, but they are moving in that direction, and they may eventually allow more personalized retreatment schedules based on quantitative fluid thresholds rather than qualitative judgment calls.